12:00 AM
 | 
Oct 27, 2008
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Intermezzo: Phase III data

In a double-blind, 3-way crossover, U.S. Phase III study in 82 patients, 1.75 and 3.5 mg of zolpidem significantly improved LPS after MOTN awakening compared to placebo (16.9 & 9.7 min. vs. 28.1 min.; p<0.001 for both). Both doses also improved TST (198 & 209 min. vs. 183 min.; p<0.001...

Read the full 228 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >